MedTrace Logo

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma

NCT01192971 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2023-03-03

No results posted yet for this study

Summary

This phase II trial will be studying how well Apatinib working in patients with Hepatocellular carcinoma.

Conditions

Interventions

DRUG

Apatinib

apatinib p.o. once daily for 4 weeks

Sponsors & Collaborators

  • Eighty-One Hospital of People's Liberation Army

    collaborator OTHER

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Shukui Qin, Dr · Nanjing Millitary Eighty-one Hosiptal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01192971 on ClinicalTrials.gov